Viva Preparation Pack
Understanding the acceptability and utility of early antiretroviral therapy to reduce transmission of HIV amongst men who have sex with men in the UKResearch title withheld — sample published with the author's permission
Epidemiology and Public Health · 82 questions
The examination will focus heavily on the tension between the biological 'utility' of early ART (based on the viral load dynamics identified in Workstream 1) and the behavioural/social 'acceptability' found in Workstream 2. I will scrutinize the candidate's use of the UK Register of HIV Seroconverters as a representative sample and the specific timeline of peak viraemia versus clinical presentation, as this is the crux of the argument regarding the feasibility of TasP in early HIV infection.
Where To Focus Your Preparation
Examiners most often decide the outcome of a viva on the questions that probe gaps,
limitations, and the significance of your contribution — not the background or
methodology questions. Based on this thesis, these are the 8 questions
most worth rehearsing first. Full guidance for each is further down, under its
category.
- 1. Your survey results (Chapter 6) rely on 'self-reported' sexual behaviour. Given the social desirability bias inherent in a clinic-based survey, why should I believe your finding that 32% of men were abstinent?
- 2. You found that 35% of men engage in 'high-risk sex' post-diagnosis. However, you define high-risk as 'condomless anal intercourse with a serodiscordant/unknown status partner'. If these men were on early ART and undetectable, is this actually 'high risk'?
- 3. Your qualitative sample (n=14) had a high proportion of men who were 'self-reflective' (Section 5.2.3). Could your 'acceptability' findings be skewed by the fact that only 'articulate, self-aware' men agreed to be interviewed?
- 4. You used the 'midpoint[extract from the author’s document removed]midpoint' closer to the real infection date than it was in 2000?
- 5. Why did you not perform a power calculation for the multivariate analysis in Chapter 6? With only 94-103 men in the final models (Table 6.12), aren't you at high risk of a Type II error?
- 6. You argue that 'Early ART reduces transmission anxiety'. Is it possible that it actually *increases* anxiety by making the infection 'real' through daily pill-taking, as hinted at in Section 5.4.2?
- 7. In Table 6.1, you show recruitment varies wildly by clinic (0% to 57%). How can you be sure your 'acceptability' findings aren't just reflecting the 'clinic culture' of the high-recruiting centres?
- 8. Your thesis title includes the word 'utility'. However, you don't actually perform any transmission modelling. Isn't 'utility' an overclaim for what is essentially an observational study of viral load and behaviour?
Understanding Your Thesis
This thesis provides a multi-dimensional analysis of the clinical and behavioural viability of 'Treatment as Prevention[extract from the author’s document removed]responsibility' and a means to alleviate transmission anxiety. However, the 'utility[extract from the author’s document removed]ChemSex') driven by treatment optimism. Ultimately, the thesis argues that while the biological and social foundations for early ART are strong, the public health impact is currently limited by the timing of diagnosis, necessitating a shift toward expanded testing to catch the window of peak viraemia.
Strengths — And How to Talk About Them
Methodological Triangulation
By combining clinical data from the UK Register with qualitative interviews and a quantitative survey (as outlined in Chapter 3), you move beyond simple epidemiology to explain *why* trends in ART initiation are occurring.
How to articulate this: Emphasize how the qualitative findings in Workstream 2 Phase A directly informed the survey items in Phase B, ensuring the quantitative tools were grounded in the actual lived experiences of MSM with recent infection.
Precision in Viral Load Modelling
The use of restricted cubic splines to model mean HIV viral load at first presentation (Figure 4.5) provides a high-resolution look at the window of infectiousness.
How to articulate this: Be prepared to discuss how this modelling allows us to pinpoint the 'missed opportunity' for intervention, reinforcing your argument that late diagnosis is the primary barrier to the utility of early ART.
Conceptualization of 'Treatment as Responsibility'
Chapter 5 identifies a shift in how ART is perceived—not just as a medical necessity for the self, but as an ethical obligation to the community.
How to articulate this: Highlight this as a key driver for 'Acceptability.' It shows that MSM are active agents in public health, which challenges older models of HIV prevention that focused solely on fear-based messaging.
Identification of 'ChemSex' as a Transmission Driver
The analysis in Section 6.5.2 and Table 6.17 correctly identifies the intersection of recreational drug use and high-risk sex post-diagnosis, which is a contemporary and critical public health concern.
How to articulate this: Present this as evidence of your work’s current relevance. You aren't just looking at ART in a vacuum; you are looking at it within the actual socio-sexual environment of the UK MSM population.
Strong Policy Implications
The thesis concludes (Section 7.3) with actionable recommendations regarding the expansion of HIV testing to capture primary HIV infection.
How to articulate this: Frame your thesis as a 'bridge' between clinical trials (like PARTNER or HPTN-052) and real-world implementation in the UK NHS context.
Weaknesses — And How to Defend Them
Selection Bias in the UK Register
Individuals enrolled in a research register (Chapter 4) are likely more engaged with healthcare than those who are not, which may lead to overestimating the acceptability and uptake of ART.
How to defend this: Acknowledge that this is a 'best-case scenario' cohort. Argue that if acceptability is high here, the focus for the harder-to-reach population must be on engagement and linkage to care, rather than the treatment itself.
Recall Bias in Survey Data
Phase B asks men to 'think back' to their diagnosis (Figure 6.3). Memories of that 'maelstrom of negative feelings' (Section 5.2.1) may be distorted by their current status on treatment.
How to defend this: Point to the qualitative data in Phase A as a 'sanity check' for the survey responses. Explain that while retrospective, these reflections are the best available proxy for understanding the decision-making process at the time of diagnosis.
Low Sample Size for Qualitative Interviews
With n=14 (Section 5.1), an examiner might question the 'thematic saturation' of your findings regarding attitudes toward early ART.
How to defend this: Defend this using the principle of 'information power.' These were in-depth, semi-structured interviews with a very specific, hard-to-recruit population (recent seroconverters), and the findings were subsequently validated in the much larger cross-sectional survey.
Temporal Gap in Guidelines
Your literature review and rationale were finalized in 2010 (Section 2.2). The field moved rapidly with the START trial and the 2015 WHO guidelines, which may make some early assumptions feel dated.
How to defend this: Position your thesis as a study of the *transition* era. Your work captures the psychological and behavioral shift that occurred as we moved from 'wait and see' to 'treat all,' providing a baseline for current practice.
Overall Defence Strategy
Your defense should focus on the concept of 'Implementation Science.[extract from the author’s document removed]early' ART isn[extract from the author’s document removed]what,' the 'how,' and the 'why' of the UK HIV epidemic.
Examination Questions
Examiner Challenges
These questions target the specific limitations, potential biases, and controversial interpretations in the thesis.
1. Your survey results (Chapter 6) rely on 'self-reported' sexual behaviour. Given the social desirability bias inherent in a clinic-based survey, why should I believe your finding that 32% of men were abstinent?
To challenge the reliability of the behavioral data.
How to approach thisDiscuss the 'anonymity' of the survey (Section 3.6.7) and the 'cognitive interviewing' which helped ensure men didn't feel judged. Compare your results with NATSAL data to show they are in a plausible range.
2. You found that 35% of men engage in 'high-risk sex' post-diagnosis. However, you define high-risk as 'condomless anal intercourse with a serodiscordant/unknown status partner'. If these men were on early ART and undetectable, is this actually 'high risk'?
To challenge the candidate's definition of risk in light of their own TasP findings.
How to approach thisDefend the definition based on the timeline. Many of these men would not yet have reached 'undetectable' status (which takes ~6 months, per the Swiss Statement), thus the risk remains biologically real.
3. Your qualitative sample (n=14) had a high proportion of men who were 'self-reflective' (Section 5.2.3). Could your 'acceptability' findings be skewed by the fact that only 'articulate, self-aware' men agreed to be interviewed?
To probe the impact of recruitment bias on the qualitative themes.
How to approach thisAcknowledge the 'volunteer bias'. Explain how you tried to mitigate this by looking for 'dissenting' voices in the framework (e.g., the 'fear and uncertainty' group) and checking these themes in the larger survey.
4. You used the 'midpoint[extract from the author’s document removed]midpoint' closer to the real infection date than it was in 2000?
To challenge the interpretation of a key temporal finding.
How to approach thisDiscuss the 'Sensitivity Analysis' in Section 4.2.5. Explain how you controlled for the 'test interval' length to ensure the trend wasn't just a result of more frequent testing.
5. Why did you not perform a power calculation for the multivariate analysis in Chapter 6? With only 94-103 men in the final models (Table 6.12), aren't you at high risk of a Type II error?
To challenge the statistical power of the survey findings.
How to approach thisExplain the constraints of the UK Register population size. Acknowledge that while power was limited, the effect sizes (ORs) were large enough to reach significance for the most critical factors like 'clinician recommendation'.
6. You argue that 'Early ART reduces transmission anxiety'. Is it possible that it actually *increases* anxiety by making the infection 'real' through daily pill-taking, as hinted at in Section 5.4.2?
To probe a contradiction in the qualitative data.
How to approach thisDiscuss the 'dual nature' of ART. It is a 'constant reminder' (anxiety-inducing) but also a 'chemical condom' (anxiety-reducing). The balance depends on the individual's 'adjustment' level.
7. In Table 6.1, you show recruitment varies wildly by clinic (0% to 57%). How can you be sure your 'acceptability' findings aren't just reflecting the 'clinic culture' of the high-recruiting centres?
To challenge the representativeness of the survey sites.
How to approach thisDiscuss the 'Study Selection' (3.6.5). Explain that the high-recruiting clinics are the largest GUM centres in the UK (e.g., 56 Dean St) and thus represent a huge proportion of the target population.
8. Your thesis title includes the word 'utility'. However, you don't actually perform any transmission modelling. Isn't 'utility' an overclaim for what is essentially an observational study of viral load and behaviour?
To challenge the candidate on the scope of their claims.
How to approach thisDefend the use of 'utility' by arguing that you provide the *inputs* for such models (VL at presentation, partner numbers, ART uptake). Without your real-world data, modelling remains purely theoretical.
9. Given the 'maelstrom of negative feelings[extract from the author’s document removed]utility'?
To push the candidate into a critical ethical debate.
How to approach thisBalance the 'autonomy' of the patient with the 'beneficence' of the health benefits (START trial data). Argue that the 'acceptability' findings suggest patients *want* to be asked, provided it is done with 'trust'.
10. You define 'early HIV infection[extract from the author’s document removed]early' category?
The candidate's temporal definition of 'early' infection is broader than standard clinical definitions and encompasses biological steady-states that differ from acute phases.
How to approach thisAcknowledge that the transition to chronic infection is a biological continuum rather than a discrete event. Defend the one-year definition by explaining how it captures the psychosocial and behavioral window during which patients first navigate a diagnosis and treatment initiation, even if the peak viraemia phase has passed.
11. Your research is heavily framed by the 2008 Swiss Statement, despite your acknowledgement that it was based on studies of heterosexual couples; what specific biological or behavioral evidence did you use to bridge the gap between that heterosexual-centric data and the high-risk receptive anal intercourse dynamics specific to the UK MSM population?
The candidate identifies the heterosexual bias of early TasP evidence but bases their thesis on its application to a different risk group (MSM).
How to approach thisIdentify the higher per-contact probability of transmission for anal versus vaginal intercourse. Defend the thesis by explaining that the focus was on 'acceptability' of the concept of viral suppression, while admitting that the absolute risk reduction might vary between different sexual acts.
12. Your methodology relies on the UK Register of HIV seroconverters, which uses RITA assays that you note can have a sensitivity as low as 42% depending on the assay—how did you account for the significant risk of misclassification in your sample, where 'early' participants might actually have been in a chronic stage of infection?
The candidate admits the technical limitations and 'inevitable misclassifications' of the RITA assays used to define their study population.
How to approach thisConcede the diagnostic limitations of RITA assays for individual-level classification. Argue that the register remains the best available proxy for identifying recent infections in the UK and discuss how any misclassified 'chronic' patients might have actually provided a useful 'delayed' perspective on treatment acceptability.
13. In your discussion of the mixed-methods approach, you describe how the two workstreams 'complement and contrast[extract from the author’s document removed]t possible from the separate phases?
The material suggests a parallel rather than fully integrated mixed-methods design, which is a common point of examiner critique.
How to approach thisAvoid describing the results as two separate chapters. Focus on 'triangulation' or 'joint displays'—show how specific qualitative insights into 'stigma reduction' helped explain or contextualize quantitative trends in treatment uptake or viraemia patterns.
14. By drawing your quantitative samples exclusively from the UK Register of HIV Seroconverters, you are focusing on a population that is engaged with specialist care and has an identifiable date of infection—how do your findings account for the perspectives of MSM who are diagnosed late or remain outside of clinical surveillance, for whom the utility of early ART might be most critical?
The UK Register is a highly specific cohort that excludes the 'hidden' population of MSM who do not test regularly or present with late-stage infection.
How to approach thisAcknowledge that the seroconverter cohort is a 'best-case scenario' for early intervention. Defend the choice by explaining that this group provides the necessary biological and behavioral data to understand the immediate post-infection window, while admitting that the results may not fully generalize to late-presenters.
15. You developed new survey items based on your qualitative interviews and used cognitive interviewing for validation—given that these items were then used to estimate prevalence, why did you not perform formal factor analysis or psychometric testing to ensure the structural validity of these new constructs before deploying the survey?
The candidate used qualitative findings to build a quantitative tool but bypassed standard psychometric validation procedures beyond basic comprehension checks.
How to approach thisExplain the rationale for using a sequential explanatory design where the qualitative work ensures high content validity. Admit that while cognitive interviews ensured the questions were understood, formal factor analysis would be the logical next step for future research to confirm the reliability of the underlying attitude constructs.
16. Your analysis of the UK Register data tracks trends in viral load and ART initiation from as early as 2009—considering the radical shift toward immediate treatment following the START and TEMPRANO trials, how do you defend the contemporary utility of findings that describe a clinical era where CD4 thresholds were still a primary barrier to treatment?
The data collection and analysis period spans a time of major clinical guideline changes, potentially rendering the 'barriers' identified in the earlier data obsolete.
How to approach thisFrame the findings as a critical historical baseline that illustrates the real-world evolution of HIV policy. Argue that understanding the transition from CD4-guided treatment to 'Test and Treat' provides essential context for current challenges in ART adherence and late presentation.
17. You were personally responsible for recruiting participants at the clinic and then conducting the in-depth interviews yourself—how did you mitigate the risk that participants viewed you as part of the clinical team, potentially leading them to over-report the 'acceptability' of early ART to please their perceived providers?
The researcher’s direct involvement in recruitment and interviewing at a clinical site introduces significant social desirability bias.
How to approach thisDiscuss the reflexive steps taken during the interview process, such as emphasizing anonymity and your role as a researcher rather than a clinician. Defend the approach by highlighting the rich, nuanced data obtained, while acknowledging that personal recruitment may have skewed the sample toward those more comfortable with clinical environments.
18. Your thesis title emphasizes the 'utility[extract from the author’s document removed]utility' for transmission reduction without incorporating phylogenetics or mathematical modeling of population-level impact?
The candidate uses individual-level proxy measures (viral load/behavior) to make claims about a population-level outcome (transmission reduction) without using appropriate modeling tools.
How to approach thisDefine 'utility' within the scope of the thesis as the clinical and behavioral feasibility of treatment as prevention. Acknowledge that while you did not model transmission directly, your work provides the high-quality individual-level parameters (acceptability, viral load, behavior) that are prerequisites for any successful public health modeling of transmission reduction.
19. Your methodology for estimating the date of seroconversion relies on a midpoint calculation for individuals with a testing window of up to 12 months, and in some cases up to three years—given the rapid viraemic peaks associated with early infection, how does this degree of temporal uncertainty compromise your ability to accurately assess the 'utility' of early ART in preventing transmission?
The candidate relies on a highly variable and potentially wide estimation window for the most critical biological period of the study: early HIV infection.
How to approach thisAcknowledge that the midpoint is a standard but imperfect convention in cohort studies. Defend the choice by highlighting the sensitivity analyses performed and the use of RITA assays to mitigate errors, while admitting that the 'utility' estimates must be interpreted as broad averages rather than precise biological snapshots.
20. You chose to exclude ethnicity from your multivariate models because 87.1% of the sample was white—how does this omission affect the generalisability of your findings to the UK's diverse MSM population, and what potential drivers of health inequality in ART acceptability might your analysis have missed as a result?
By omitting ethnicity due to low numbers, the candidate risks ignoring the specific barriers or needs of minoritised groups who are often disproportionately affected by HIV.
How to approach thisExplain the statistical trade-off between power and granularity, acknowledging that grouping disparate non-white ethnicities can produce misleading results. However, admit that this limits the thesis's ability to address intersectional barriers and suggest that future targeted studies are needed for these specific subpopulations.
21. Your qualitative interviews were conducted exclusively at a single central London clinic—given the unique density of HIV-specialist services and gay social infrastructure in the capital, why should we believe that the 'attitudes and beliefs' you identified are representative of MSM living in more rural or less-served areas of the UK?
London is a highly specific context for HIV care, and findings from one clinic may not reflect the experiences of MSM in areas with higher stigma or fewer resources.
How to approach thisAccept that the London-centric nature of the sample is a limitation. Argue that the chosen clinic provided the necessary volume of recent diagnoses for the study, but concede that the 'acceptability' findings likely represent an optimistic or well-supported scenario that may not apply nationwide.
22. You explicitly excluded individuals who had a 'severe psychological reaction[extract from the author’s document removed]acceptability' of immediate ART initiation?
The exclusion of participants with acute psychological distress removes those for whom the 'utility' of early ART is most likely to be complicated by mental health or adherence issues.
How to approach thisDefend the exclusion on ethical grounds regarding the protection of vulnerable participants during a crisis. However, acknowledge that this creates a 'healthy participant bias' where the reported acceptability of early ART may be higher than it would be in a truly representative clinical population.
23. You state that no pre-existing social or psychological theory was used to underpin the development of your interview topic guide—without a theoretical lens, such as the Health Belief Model or the Theory of Planned Behaviour, how did you ensure your analysis moved beyond a descriptive summary to a robust, explanatory model of ART uptake?
The lack of a theoretical framework in qualitative research can lead to purely descriptive results that lack the analytical depth required to explain 'why' certain behaviours occur.
How to approach thisExplain that the choice was intended to avoid 'shoehorning' participant experiences into rigid, pre-conceived categories in an exploratory study. Defend the rigour of the Framework approach as a systematic way to generate themes from the ground up, while acknowledging that later applying a theoretical lens might have enriched the explanatory power of the results.
Contribution and Significance
This category explores the real-world impact and the candidate's ability to provide policy recommendations.
24. You conclude that early ART is 'unlikely to be effective in reducing transmission during peak viraemia'. Given this, should the UK stop focusing on 'Early ART' and instead shift all resources to 'Frequent Testing'?
To push the candidate on their primary policy recommendation.
How to approach thisArgue that the two are inseparable. Frequent testing is the 'case-finding' mechanism, but without the 'acceptability' of early ART, finding those men doesn't result in reduced transmission.
25. How does your finding on 'clinician recommendation' being a primary driver of ART initiation (Chapter 6.4) change the way we should train GUM (Genitourinary Medicine) physicians?
To translate findings into clinical practice recommendations.
How to approach thisSuggest moving away from a 'neutral' presentation of options toward a 'pro-active' recommendation of early ART, while still maintaining the patient's agency as identified in the qualitative work.
26. What is the single most important 'novel' finding in your thesis that wasn't already suspected by the SPARTAC or START trials?
To define the candidate's original contribution to the field.
How to approach thisFocus on the 'acceptability' data and the specific viral load modeling in a 'real-world' UK clinic setting, rather than the controlled environment of a clinical trial.
27. Your thesis focuses on MSM. How transferable are your findings regarding 'ART as empowerment' (5.4.3) to other high-risk groups in the UK, such as the Black African heterosexual community?
To test the boundaries of the study's significance.
How to approach thisDiscuss the different drivers of stigma (e.g., cultural vs sexual identity) and whether the 'empowerment' through sexual risk reduction is as relevant in different relationship structures.
28. Based on Figure 7.1, your final conceptual framework, what is the 'weakest link' in the chain of using early ART to reduce HIV transmission in the UK?
To assess the candidate's critical view of the public health pathway.
How to approach thisIdentify the gap between infection and first clinic presentation (the 'hidden' period). Argue that all the 'acceptability' in the world can't fix a lack of diagnosis.
29. How should your findings on 'transmission anxiety' (5.4.1) influence the way 'TasP' is marketed to the public? Should we lead with 'Protect Your Health' or 'Protect Your Partners'?
To probe the communication implications of the research.
How to approach thisReference the 'ART as a source of empowerment' theme. Suggest a dual-messaging approach, but highlight that for many MSM, the 'altruistic' benefit (protecting others) was a powerful psychological driver.
30. You mention 'PrEP' (Pre-exposure prophylaxis) in your abbreviations but it doesn't feature heavily in your analysis. How does the rise of PrEP since 2014 change the 'utility' of your findings on early ART?
To see if the candidate can update their findings in a changing landscape.
How to approach thisAcknowledge the shift in the prevention landscape. Explain that early ART and PrEP are synergistic; early ART reduces the 'source' viraemia while PrEP reduces 'susceptibility'.
31. What specific change to BHIVA guidelines would you propose based on your findings in Chapter 6 regarding 'Short-course' vs 'Long-term' ART acceptability?
To test the candidate's ability to influence clinical guidelines.
How to approach thisPropose that guidelines should emphasize the 'psychological' timing of the offer, perhaps suggesting a 'two-step' process where the offer is made at diagnosis but revisited 4 weeks later after the initial shock has subsided.
32. Your work mentions 'HIV criminalisation' (Section 1.1). Did your participants mention fear of the law as a reason to start ART, and how does this affect the 'ethics' of promoting ART as a responsibility?
To explore the ethical/legal dimensions of the work.
How to approach thisRefer to the qualitative data on 'ART as a source of fear'. Discuss the tension between public health 'utility' and individual 'liberty', and how effective ART can be a 'legal' protective factor.
33. If you had a limited budget, would you spend it on increasing the 'acceptability' of early ART among those already diagnosed, or on a 'Testing' campaign to find those in the first 30 days?
To force a prioritization of findings.
How to approach thisDefend the 'Testing' campaign based on the Workstream 1 findings about peak viraemia, while noting that the 'acceptability' work ensures the testing campaign leads to actual viral suppression.
Methodology and Methods
These questions scrutinize the candidate's handling of the UK Register data, the rigour of the qualitative coding, and the validity of the survey design.
34. In Chapter 4.2.3, you use restricted cubic splines to model viral load. Why did you choose this over a simple non-parametric regression, and how sensitive were your 'peak' estimates to the placement of the knots?
To test statistical depth and the robustness of the central finding in Workstream 1.
How to approach thisExplain that splines allow for the non-linear relationship of VL post-seroconversion (the rapid rise and fall). Discuss how you tested different knot positions to ensure the peak at ~30 days wasn't an artifact of the model.
35. You recruited only 14 participants for your in-depth interviews. Given that these were all recruited from a single central London clinic, to what extent can you claim to have reached thematic saturation for MSM across the UK?
To challenge the generalizability and sufficiency of the qualitative sample.
How to approach thisDefend the sample by describing the richness of the framework analysis (Appendix 14) and how these themes were then 'tested' and validated in the UK-wide survey of 117 men.
36. Regarding the UK Register of HIV Seroconverters: since the midpoint between the last negative and first positive test is used as the proxy for seroconversion, how did you account for the potential 'interval bias' in your analysis of time to ART initiation?
To probe a common weakness in seroconverter cohort studies.
How to approach thisDiscuss the sensitivity analysis or the inclusion criteria (test interval <12 months). Explain how wider intervals might 'blur' the peak viraemia data and why you prioritized RITA-confirmed dates where possible.
37. In Table 3.1, you detail the coding for HIV-1 RNA assays. How did you handle the historical transition from branched DNA (bDNA) to PCR assays in your temporal trend analysis from 2000 to 2011?
To test technical attention to detail in longitudinal data cleaning.
How to approach thisExplain the standardization process for log copies/mL and whether you adjusted for the different lower limits of detection (e.g., 50 vs 40 copies) when defining 'suppression'.
38. Your qualitative analysis used a 'Framework Approach[extract from the author’s document removed]experience' of diagnosis?
To test the candidate's understanding of qualitative methodologies.
How to approach thisArgue that Framework Analysis is better suited for applied policy research where you have pre-defined objectives (acceptability of ART) but want to allow themes to emerge across a diverse team (supervisors).
39. For the cross-sectional survey (Workstream 2, Phase B), you had a 52% response rate (Table 6.1). How did you determine that the 'non-responders' were not fundamentally different in terms of their 'treatment optimism'?
To probe for non-response bias in the survey findings.
How to approach thisRefer to Table 6.2, comparing responders and non-responders on available clinical data (CD4, age). Acknowledge that while clinical markers were similar, attitudinal differences are an unavoidable limitation of survey research.
40. You performed 'cognitive interviews' to validate your survey (Section 3.6.3). Can you give a specific example of a question that was misinterpreted by participants and how you subsequently refined it?
To see evidence of the iterative design process.
How to approach thisDescribe a specific change from Appendix 17, such as the wording around 'ChemSex' or 'High-risk sex', and how the participants' feedback improved the question's clarity.
41. In your multivariate analysis of factors associated with early ART (Table 6.12), you used a hierarchical approach. Why was 'Time from diagnosis' included in the base model rather than treated as a potential confounder to be removed?
To test the logic of the statistical modelling.
How to approach thisExplain that 'Time from diagnosis' is a fundamental determinant of the opportunity to start ART; adjusting for it ensures that findings aren't simply reflecting who has been in the clinic longer.
42. Why did you exclude MSM who had acquired HIV through IDU from certain analyses? Does this not omit a critical sub-population where 'utility' of early ART is high for preventing further transmission?
To probe the inclusion/exclusion criteria.
How to approach thisExplain that the drivers of sexual transmission and needle-sharing transmission are different, and for the sake of a focused PhD, the 'MSM sexual transmission' pathway (ChemSex vs IDU) was the priority.
43. How did you ensure 'reflexivity' during your in-depth interviews? As a researcher, how did your presence potentially influence the 'shock' narratives men shared with you?
To test qualitative rigour and self-awareness.
How to approach thisDiscuss your positionality as a female researcher in a predominantly male sexual health space. Reference how you built rapport and whether you felt participants 'performed' a certain type of 'responsible' patient identity for you.
Findings and Analysis
This category probes the core results, specifically the viral load peaks and the behavioral changes post-diagnosis.
44. Your data in Figure 4.4 shows a wide scatter of viral loads at presentation. Given that some men present with relatively low VL even in EHI, is the 'TasP' argument for early ART weakened for these 'low-viremic' individuals?
To challenge the universal application of the candidate's findings.
How to approach thisArgue that while individual risk is lower, the population-level 'utility' still relies on suppressing those who *do* have high VL. Mention that early ART also prevents the 'set point' from being high.
45. You found that median time to ART initiation dropped from 3.7 to 1.4 years (Chapter 4.1.2). Is this change driven by patient acceptability or simply by changing BHIVA guidelines during that decade?
To distinguish between structural and individual drivers of the findings.
How to approach thisAnalyze the temporal trends alongside the guideline changes (Section 1.1). Suggest that it is a 'pincer movement' of clinicians being more comfortable prescribing and patients being more 'optimistic' about modern drugs.
46. In Chapter 5.4.1, you discuss 'ART as a responsibility'. Did you find any evidence that this sense of responsibility leads to 'hidden' non-adherence, where men start ART to please their doctor but don't take it?
To probe the limits of the 'acceptability' finding.
How to approach thisDraw on the 'fear and uncertainty' theme (5.4.2). Explain that while men verbalize responsibility, the 'toxicities' fear suggests a conflict that could lead to sub-optimal adherence, which your survey wasn't longitudinal enough to capture.
47. Table 6.13 shows a significant reduction in partner numbers post-diagnosis. However, 35% still engage in high-risk sex. Is the 'utility' of early ART undermined by the fact that those with the highest VL are also those most likely to enter a period of sexual abstinence immediately after diagnosis?
To probe the behavioral paradox in the data.
How to approach thisDiscuss the 'adjustment' period (5.2.2). The 'utility' is actually greatest for the 35% who *don't* abstain. Early ART acts as a safety net for those who return to high-risk sex quickly.
48. You found that 'Treatment Optimism' was associated with high-risk sex (Table 6.18). Does this suggest that promoting the 'utility' of early ART for prevention might actually be counter-productive for public health?
To challenge the candidate on the 'Risk Compensation' debate.
How to approach thisCarefully weigh the benefits of TasP against the findings. Argue that optimism is a sign of health recovery, but it must be paired with clear communication about when 'undetectable' is actually reached.
49. In Figure 4.5, you show VL plateauing around day 100. What is the biological or immunological significance of this plateau in the context of the UK MSM epidemic?
To test the candidate's understanding of HIV pathogenesis.
How to approach thisExplain the transition from acute to early chronic infection and the establishment of the 'viral set point'. Discuss why this period is still a 'high transmission' risk compared to long-term chronic infection.
50. Your survey found that 67% of men would have accepted ART at diagnosis (Abstract). Why is there such a gap between this 'hypothetical' acceptability and the 47% actual uptake you observed?
To probe the 'intention-behavior' gap in the data.
How to approach thisRefer to the qualitative findings on 'shock' and 'fear' (Chapter 5). Hypothetically, men want the benefit, but the reality of daily medication during a traumatic life event (diagnosis) creates a barrier.
51. How do you explain the finding in Table 6.15 that having an STI at diagnosis was NOT significantly associated with early ART initiation, given that STIs increase the urgency for TasP?
To probe an unexpected negative finding.
How to approach thisDiscuss whether clinicians or patients prioritized treating the STI first, or whether the HIV diagnosis was so overwhelming that the 'prevention' benefit of ART was secondary to immediate STI management.
52. In your analysis of 'ChemSex' (Section 6.5.2), did you find that drug use was a barrier to ART initiation (due to fear of interactions) or a driver (due to increased risk perception)?
To explore the nuanced role of drug use in the findings.
How to approach thisReference Table 6.12 and 6.17. Note that while ChemSex is linked to high-risk behavior, its relationship with ART initiation is complex, often mediated by the level of 'control' a man feels over his life (Bandura’s agency).
53. Why did you find that 'higher education level' was associated with early ART initiation in your multivariate model? What does this say about the 'utility' of TasP in more marginalized MSM populations?
To probe health inequalities in the findings.
How to approach thisDiscuss health literacy and the ability to process the 'complex nuances' of the Swiss Statement. Suggest that TasP as a strategy may widen health gaps if not supported by targeted education for those with lower educational attainment.
54. Your research adopts a sequential mixed-methods design where qualitative findings directly informed the development of a cross-sectional survey. How do you defend the validity of your survey instruments, given they rely on items newly developed from your specific interview cohort rather than solely on established, externally validated scales?
The examiner is testing the candidate's understanding of instrument development and the methodological rigor of transitioning from qualitative themes to quantitative measures.
How to approach thisThe candidate should discuss the process of 'thematic translation[extract from the author’s document removed]content validity' that is specific to the UK MSM population with early HIV infection, which generic scales might miss.
55. In your analysis of the UK Register of HIV Seroconverters data, you examined trends in viral load at presentation and time to ART initiation. How do these clinical markers of 'utility' reconcile with the 'acceptability' findings from your qualitative phase, particularly where patient priorities might have conflicted with clinical recommendations for early treatment?
The examiner is looking for evidence that the candidate can synthesize clinical data with psychosocial data to address the 'utility vs. acceptability' tension central to the thesis.
How to approach thisThe candidate should contrast the epidemiological necessity of low viral loads for transmission reduction with the personal, emotional, and social factors they uncovered in interviews. They should discuss how 'utility' is a multi-level construct—clinical for the population and personal for the individual.
56. Your survey sought to identify factors associated with behaviors carrying a high risk of HIV transmission after diagnosis. Given the self-reported nature of this data among MSM recruited to a register, how do you address the potential for social desirability bias in your findings on the utility of early ART for transmission reduction?
This question addresses a common limitation in behavioral epidemiology and tests the candidate's critical appraisal of their own quantitative data.
How to approach thisThe candidate should acknowledge the limitations of self-reported sexual behavior and discuss the strategies used to mitigate bias, such as questionnaire design or the anonymity of the survey. They could also argue that those engaged in a research register might have different reporting behaviors than the general population.
57. You were responsible for the end-to-end management of the cross-sectional survey, including the logistics of NHS ethics and R&D approvals across multiple clinics. How did this extensive fieldwork and clinic liaison affect your interpretation of the 'acceptability' of early ART from a service-delivery perspective?
The examiner is probing the candidate's understanding of the practical and systemic barriers to implementing early ART in a real-world clinical setting.
How to approach thisThe candidate should reflect on their interactions with clinic staff and investigators to discuss 'acceptability' not just from the patient's side, but from the provider's side. They should discuss how clinic-level factors might influence a patient's decision-making process.
58. Your research includes a co-authored review and several conference presentations on viral load trends and early ART. How does your thesis specifically build upon or diverge from the conclusions presented in the Hamlyn et al. review article you contributed to?
This tests the candidate's ability to distinguish their independent contribution from the work of their wider research group or co-authors.
How to approach thisThe candidate should clearly delineate their unique findings—likely the mixed-methods integration and the specific focus on MSM attitudes—from the more general clinical or epidemiological findings of the co-authored review.
59. One of your aims was to estimate the prevalence of certain attitudes toward early ART in a UK-wide population of MSM. How do you defend the representativeness of your UK Register sample, and what are the implications for the generalisability of your findings to MSM who are diagnosed outside of major urban HIV centers?
This is a fundamental question on sampling bias and the external validity of the study's conclusions.
How to approach thisThe candidate should discuss the characteristics of the UK Register of HIV Seroconverters and acknowledge any geographic or demographic skews. They should then explain how these limitations should be taken into account when applying the findings to national policy or different clinical contexts.
60. Your thesis highlights the 2008 Swiss Statement as a pivotal moment that shifted the discourse on infectiousness. How does your research reconcile the initial reticence of healthcare professionals regarding 'zero risk' with the contemporary acceptability of early ART among MSM in the UK?
The examiner is probing how the candidate situates their findings within the historical and professional debates surrounding Treatment as Prevention (TasP).
How to approach thisThe candidate should discuss how their qualitative or quantitative data reflects current attitudes toward the 'undetectable = untransmittable' concept. They should acknowledge the tension between clinical caution and the 'liberating' potential of the statement for the MSM community.
61. You adopted a mixed-methods approach to investigate the acceptability and utility of early ART. In your view, what specific insights did the qualitative components provide regarding 'risk compensation'—a concern raised following the Swiss Statement—that the epidemiological data alone could not capture?
The examiner is testing the candidate's understanding of the added value of mixed methods in addressing complex behavioral questions.
How to approach thisThe candidate should explain how interviews or surveys captured the nuances of behavioral change, such as 'strategic positioning' or changes in condom use, providing a depth of context that $R_0$ modeling or clinical data lacks.
62. Your research defines Early HIV Infection (EHI) as the first year following infection, distinct from 'primary' or 'acute' phases. How do you defend this specific temporal boundary, and how did it influence your analysis of ART utility given the rapid viral dynamics described in the Fiebig stages?
The examiner is questioning the methodological decision-making regarding clinical definitions and their impact on data interpretation.
How to approach thisThe candidate should justify the one-year window by referencing clinical relevance, data availability (e.g., from the UK Register), and the typical timeframes for seroconversion and viral set-point stabilization.
63. Your thesis utilizes the May and Anderson model alongside Boerma and Weir’s framework of proximate determinants. How do you defend the use of these classical models in the context of a mature epidemic among MSM, where sexual mixing patterns and background prevalence significantly complicate the 'c' parameter?
The examiner is looking for a critical evaluation of the theoretical frameworks used to explain HIV transmission dynamics.
How to approach thisThe candidate should demonstrate an awareness of the limitations of simple $R_0$ equations in non-susceptible populations and explain how they adjusted their thinking or analysis to account for 'exposure of susceptible to infected persons' rather than just partner acquisition rates.
64. While your analysis notes that subtype B remains the predominant HIV-1 subtype among UK MSM, you also highlight the emergence of non-B subtypes. To what extent does your research account for the different disease progression rates and 'set points' associated with these diverse subtypes when assessing the utility of immediate ART initiation?
The examiner is probing the candidate's depth of knowledge regarding viral diversity and its implications for public health strategy.
How to approach thisThe candidate should discuss whether their data allowed for subtype-specific analysis or, if not, how the increasing diversity of the UK epidemic might limit the generalizability of their findings across different MSM sub-populations.
65. Your thesis bridges the transition from clinical guidelines recommending ART at CD4 <350 to the current focus on immediate initiation. How do your findings on 'acceptability' challenge or support the results of the START and SPARTAC trials you cite?
This question assesses the candidate's ability to integrate their own research findings with landmark clinical trial data.
How to approach thisThe candidate should contrast the 'clinical utility' (individual health outcomes) with 'behavioral acceptability' (the willingness of individuals to start treatment early), highlighting any disconnects between trial outcomes and real-world implementation among UK MSM.
66. Your thesis utilizes Boerma and Weir’s proximate-determinants framework, specifically the biological parameters of per-contact risk, exposure, and duration of infectiousness. Why did you select this specific model over other socio-ecological frameworks to bridge the biological utility and behavioral acceptability of early ART?
The examiner wants to see if the candidate can justify their theoretical grounding and explain how a biological model accommodates the social and psychological aspects of 'acceptability'.
How to approach thisFocus on how the framework allows for a clear link between clinical outcomes (utility) and the human behaviors that drive those outcomes. Explain that while it is a biological model at its core, the 'proximal determinants' provide a structured way to categorize the attitudinal and behavioral data collected in the mixed-methods workstreams.
67. In your analysis of the UK Register of HIV Seroconverters, you define 'utility' through the lens of viral load at first clinic presentation. How do you defend the reliance on this clinical registry data to represent the broader population of MSM with early HIV infection who may not present to clinics as rapidly as those captured in the Register?
This probes the candidate's understanding of selection bias and the limitations of using registry data to make population-level claims about transmission utility.
How to approach thisAcknowledge the potential for 'healthy volunteer' or 'early presenter' bias in the Register. Discuss the inclusion criteria (such as RITA assays and symptom-based diagnosis) and argue how these specific metrics still provide a valid, if conservative, estimate of the potential for early ART to intercept high viraemia.
68. For your in-depth interview study, you chose to purposively sample based solely on age. Given that ethnicity and educational level are significant factors in HIV-related health inequalities in the UK, how do you justify the exclusion of these variables from your sampling quota, and what might your findings have missed as a result?
The examiner is questioning the rigor of the qualitative sampling strategy and its impact on the breadth of the findings regarding acceptability.
How to approach thisExplain the pragmatic constraints mentioned in the research (recruitment speed and clinic demographics) but critically reflect on how different cultural or socio-economic backgrounds might influence 'acceptability' or trust in early clinical intervention. Frame this as a limitation that informs the interpretation of the results.
69. You integrated items from the ASTRA, SHARPN, and GMSHS studies into your cross-sectional survey. While this allows for cross-comparison, how did you ensure these validated items remained sensitive to the unique psychological context of men in the 'early' phase of infection compared to the chronic populations those studies originally targeted?
This tests the candidate’s methodological sensitivity to the timing of the HIV journey and the validity of 'borrowing' instruments across different disease stages.
How to approach thisDiscuss the use of cognitive interviewing and the 'sequential' nature of the mixed methods. Explain how the eight initial interviews helped identify where existing items from chronic-focused studies needed adaptation to capture the specific shock or urgency associated with early HIV infection (EHI).
70. Your research design follows a sequential mixed methods approach, yet you noted that survey development began after only eight interviews due to time constraints. To what extent do you feel this pragmatic compromise affected the depth of the 'acceptability' metrics you were able to quantify in the survey phase?
The examiner is probing the integrity of the mixed-methods design and whether the 'sequential' element was truly achieved or merely aspirational.
How to approach thisBe honest about the trade-off between rigour and timeline. Detail specific themes that *were* captured in those first eight interviews—such as the expectation of immediate treatment—and explain how they were successfully operationalized into survey questions, while acknowledging what might have been missed from later transcripts.
71. In your statistical modeling of temporal trends in viral load, you employed restricted cubic splines with five knots. What was your rationale for this specific number of knots, and how did you verify that this approach did not result in over-fitting your data compared to a simpler linear or categorical model?
This is a technical check on the candidate’s statistical literacy and their ability to justify complex modeling choices for longitudinal data.
How to approach thisReference the methodology used (such as Harrell’s recommendations) and the use of likelihood ratio tests to compare the spline model against simpler models. Explain that five knots provide a balance between flexibility to capture non-linear trends in viral load over time and the risk of over-fitting to noise in the data.
72. Your thesis posits that attitudes toward early ART are shaped by the experience of diagnosis and its aftermath. Based on your qualitative findings, how should the clinical 'utility' of immediate ART initiation be balanced against the potential psychological harm of rushing treatment decisions during the acute phase of diagnosis?
This is a 'big picture' question asking the candidate to synthesize their findings into a policy or clinical recommendation.
How to approach thisSynthesize the 'utility' findings (the need to hit high viraemia early) with 'acceptability' findings (the need for psychological processing time). Suggest a clinical model—perhaps 'supported' rapid initiation—that acknowledges the biological urgency while providing the psychological scaffolding identified as necessary in the interviews.
Research Design and Conceptual Framework
This category tests the candidate's ability to integrate epidemiological modelling with social science frameworks like Bandura's self-efficacy.
73. You utilize Boerma and Weir’s conceptual framework for the proximate determinants of sexual transmission. How did you reconcile this biologically-focused framework with Bandura’s concepts of agency and self-efficacy when interpreting the qualitative findings in Chapter 5?
To see if the candidate can bridge the gap between social cognitive theory and epidemiological transmission models.
How to approach thisDiscuss how the proximal determinants (like viral load and contact rate) are influenced by the individual's 'agency' to start ART or modify sexual behaviour. Reference the 'ART as responsibility' theme in your qualitative data as a mediator for these determinants.
74. In Figure 3.2, you present your own conceptual framework. Why did you place 'Clinician recommendation' as a direct driver of acceptability rather than a mediator of 'Trust', given your qualitative findings on the importance of the doctor-patient relationship?
To probe the structural logic of the candidate's original theoretical contribution.
How to approach thisJustify the placement by citing your multivariate analysis in Table 6.12, where clinician recommendation was a statistically significant factor for early ART initiation independently of general attitudes.
75. Your research question explicitly links 'acceptability' and 'utility'. Based on your findings in Chapter 4 regarding the timing of peak viraemia, is 'acceptability' of early ART actually relevant if the transmission utility is largely lost by the time most men present to clinic?
To challenge the candidate on the practical alignment of their two main variables.
How to approach thisAcknowledge the 'missed window' (peak viraemia at ~30 days vs presentation). Argue that acceptability remains crucial for the 'plateau' phase (~100 days) and for long-term viral suppression, even if the absolute peak is missed.
76. How did the 'Swiss Statement' of 2008 specifically shape the way you designed your interview topic guide regarding 'transmission optimism'?
To assess the candidate's responsiveness to the specific historical context of their study.
How to approach thisRefer to the 'Rationale' section (1.1). Explain how the Swiss Statement necessitated questions about whether men perceived themselves as 'uninfectious' and how that influenced their willingness to start ART early.
77. You define 'Early HIV Infection[extract from the author’s document removed]utility' is so front-loaded?
To probe the consistency of the operational definitions used across different methods.
How to approach thisExplain the trade-off between biological precision (acute phase) and the practicalities of recruitment in the UK Register. Argue that the 12-month window is necessary to capture the psychological 'adjustment' phase identified in your qualitative work.
78. In your literature review, you cite the HPTN-052 trial. To what extent did the predominantly heterosexual focus of that trial limit your ability to form hypotheses about UK MSM regarding 'risk compensation'?
To test the candidate's critical appraisal of the evidence base.
How to approach thisDiscuss the differences in sexual networks and act-specific transmission risks (Table 1.1) between heterosexual and MSM populations. Note that HPTN-052 didn't account for 'ChemSex', which you found to be a significant factor for your cohort.
79. You distinguish between 'felt stigma' and 'enacted stigma' using Scambler’s work. How did this distinction specifically influence your multivariate model for ART initiation in Table 6.11?
To ensure the theoretical concepts were actually operationalized in the statistics.
How to approach thisPoint to the specific survey items regarding 'fear of toxicities' vs 'fear of being identified as HIV+'. Explain how 'felt stigma' was captured through the 'shame' and 'secrecy' items in the survey.
80. Why did you choose a mixed-methods approach rather than a purely quantitative longitudinal study, which might have better tracked the 'utility' of ART over time as viral loads dropped?
To test the candidate's methodological justification.
How to approach thisArgue that quantitative data alone cannot explain *why* some men refuse ART despite high viral loads. Reference the 'maelstrom of negative feelings' in Chapter 5 which provides context that a longitudinal VL study would miss.
81. Your definition of 'early ART' includes both short-course and long-term initiation. How does this lack of distinction in your primary research question impact your ability to advise on BHIVA policy, which treats these as different clinical pathways?
To probe the policy-relevance of the candidate's definitions.
How to approach thisAcknowledge the clinical distinction but defend the unified approach based on the 'acceptability' perspective—to the patient at diagnosis, the immediate hurdle is starting *any* pills, regardless of the planned duration.
82. Given your focus on the UK context, why did you not incorporate more of the 'Social Ecology' model to account for the impact of NHS structural barriers, rather than focusing so heavily on individual psychology?
To probe the limitations of the chosen conceptual framework.
How to approach thisExplain that since ART is free at the point of use in the UK (Section 1.3.2), individual and clinician-level factors are the primary variables of interest compared to countries with insurance-based barriers.